by Ashok Kuumar | Jul 18, 2020 | Insurance
APOLLO MUNICH HEALTH INSURANCE is now become HDFC ERGO HEALTH INSURANCE
As you are aware that HDFC ERGO is General Insurance Company and Apollo Munich was only serving in HEALTH INSURANCE.
Health Insurance Agency License of APOLLO MUNICH was allotted based on your LIFE INSURANCE Agency License. And Now after Merger of HDFC ERGO & APOLLO MUNICH agent are in pain. Because 100% chance to loose all business, which they have done earlier or Existing Agent need to take General Insurance Agency License after passing IC38 Examination. If Existing Agent not pass IC38 then He/She will loose all business.
In earlier Phase HDFC ERGO AND APOLLO team was giving information to existing agent for taking General Insurance Agency, However they realize that current existing policy from Apollo Munich start porting from Apollo to other Companies. Therefor they decided to hide information about General Insurance License. And now telling lie that No need to worry for Existing Agents of APOLLO MUNICH.
My personal recommendation to take General Insurance License earlier to avoid last time rush or business loss of APOLLO Munich.
If you have already License of General Insurance from other companies then Please take NOC- No Objection Certificate from APOLLO MUNICH ( HDFC ERGO) and start New Code in STAR HEALTH.
STAR HEALTH is just like APOLLO MUNICH, so you can take agency of Star Health without any expense and you can shift all your current business from APOLLO to STAR HEALTH.
Which will safe your current businesses without any loss.
If you need any assistant to Join STAR HEALTH Please Feel free to Call @ 9891423442
by Ashok Kuumar | Jul 17, 2020 | Mutual Fund
OPEN DEMAT ACCOUNT CLICK HERE , ONLINE INVESTMENT IN Mutual FUNDS CLICK HERE
Franklin Templeton Mutual Fund is expecting to receive a total of Rs 6,000 crore until September-end in the six debt schemes that were wound up on April 23, 2020 said Santosh Kamath, Managing Director & Chief Investment Officer-Fixed Income in podcast sent to investors and distributors.
Giving the break up of Rs 6,000 crore, Kamath said that six schemes received cash flows of Rs 3,275 crore from April 24-June 30, 2020 without doing any secondary market sale.
“The schemes would potentially receive an additional Rs 3,200 crore from July 1-Sep 30, 2020. This will take the total over Rs 6,000 crore from April 24 to Sep 30,” Kamath said.
On April 23, Franklin Templeton Mutual Fund had said it would wind up six schemes – Franklin India Low Duration Fund, Franklin India Dynamic Accrual Fund, Franklin India Credit Risk Fund, Franklin India Short Term Income Plan, Franklin India Ultra Short Bond Fund and Franklin India Income Opportunities Fund – citing severe illiquidity and redemption pressures caused by the COVID-19 pandemic.
A podcast with Kamath highlighted on the thought process behind his investment decisions and monetising the investments.
Kamath said, “In order to sell efficiently in the secondary market government securities, or AAA paper curve should be at a lower level, liquidity in the market should be good, it should be easy for corporates to access money from the banking system and market should see a normalised risk appetite.”
Giving rationale on Franklin Templeton MF being the only subscriber to bond issues of certain companies , he said Vastu Home Finance where the fund house was the predominant holder was upgraded recently in a difficult market environment showing strength of the company.
Kamath said, “We also had investments invested in AU Finance, Equitas Finance, Tata Sky, Mahindra World City, when we were among the only investor in those companies then and it turned out quite well for the schemes. AU Finance – a small NBFC turned into itself into a bank. Equitas –same story, a small NBFC turned into itself into a bank. Tata Sky got upgraded and many investors started buying those paper and therefore spreads came down and that’s true for Mahindra City and many such names.”
Concluding the podcast, Kamath said that 2 schemes – Franklin India Ultra Short Bond Fund and Franklin India Dynamic Accrual Fund – which have paid up all their borrowings and are cash positive.
In fact, Franklin India Ultra Short Bond Fund has 13 percent of its AUM in cash as of June 30th.
Other two schemes—Franklin India Credit Risk Fund and Franklin India Low Duration Fund, the borrowing level has come down to sub 10 percent from their original levels on April 24,2020.
by Ashok Kuumar | Jul 11, 2020 | Investments, Shares
OPEN ZERODHA DEMAT Account in 10 minutes- CLICK HERE
Incorporated in 2009, Rossari Biotech Ltd is a manufacturer of textiles specialty chemicals. It provides customized solutions to the apparel, animal & poultry feed, and FMCG industries by offering a diversified product portfolio. Rossari Biotech operates in 18 countries including India, Bangladesh, Vietnam, and Mauritius.
As per the F&S Report published on 30th Sept 2019, it is the largest textile specialty chemical manufacturer in India. The business of the company can be classified into three main categories which are textile specialty chemicals; animal health & nutrition products; and home, personal care & performance chemicals. The company has 1,948 different products range under these three categories.
Most of the products of the company are manufactured in-house. It has a manufacturing unit located at Silvassa, Dadra & Nagar Haveli with an installed capacity of 100,000 MTPA. The company is also setting up a manufacturing unit at Dahej in Gujarat with an installed capacity of 132,500 MTPA. Rossari Biotech also has two R&D facilities in Silvassa and Mumbai locations to focus on new product development, formulations, and cost competitiveness. It has more than 194 distributors across India and 27 distributors spread in other 17 countries.
Competitive Strengths
1. Diversified product portfolio
2. Well-known textile specialty chemical manufacturer in India
3. In-house manufacturing unit
4. Strong R&D facility
5. Pan-India distribution network
Company Promoters:
Mr. Edward Menezes and Mr. Sunil Chari are the promoters of the company.
Company Financials:
Summary of financial Information (Restated)
| Particulars |
For the year/period ended (₹ in Million) |
|
31-Mar-20 |
31-Mar-19 |
31-Mar-18 |
31-Mar-17 |
| Total Assets |
4,715.15 |
2489.45 |
1649.50 |
1308.94 |
| Total Revenue |
6,038.18 |
5171.24 |
3004.29 |
2605.97 |
| Profit After Tax |
652.53 |
456.83 |
254.03 |
142.85 |
Objects of the Issue:
The net proceeds of the Fresh Issue, i.e. Gross proceeds of the Fresh Issue less the Offer Expenses apportioned to the Company (“Net Proceeds”) are proposed to be utilised in the following manner:
1. Repayment/prepayment of certain indebtedness availed by the Company (including accrued interest);
2. Funding working capital requirements; and
3. General corporate purposes
Rossari Biotech IPO Details
| IPO Date |
Jul 13, 2020 – Jul 15, 2020 |
| Issue Type |
Book Built Issue IPO |
| Issue Size |
11,682,033 Eq Shares of ₹2
(aggregating up to ₹496.49 Cr) |
| Fresh Issue |
[.] Eq Shares of ₹2
(aggregating up to ₹50.00 Cr) |
| Offer for Sale |
10,500,000 Eq Shares of ₹2
(aggregating up to ₹[.] Cr) |
| Face Value |
₹2 Per Equity Share |
| IPO Price |
₹423 to ₹425 Per Equity Share |
| Market Lot |
35 Shares |
| Min Order Quantity |
35 Shares |
| Listing At |
BSE, NSE |
| P/E (x) |
33.81 |
| Market Cap (₹ Cr.) |
2207 |
Rossari Biotech IPO Tentative Date / Timetable
| Bid/Offer Opens On |
Jul 13, 2020 |
| Bid/Offer Closes On |
Jul 15, 2020 |
| Finalisation of Basis of Allotment |
Jul 20, 2020 |
| Initiation of Refunds |
Jul 21, 2020 |
| Credit of Shares to Demat Acct |
Jul 22, 2020 |
| IPO Shares Listing Date |
Jul 23, 2020 |
Rossari Biotech IPO Lot Size and Price (Retail)
| Application |
Lots |
Shares |
Amount (Cut-off) |
| Minimum |
1 |
35 |
₹14,875 |
| Maximum |
13 |
455 |
₹193,375 |
Rossari Biotech IPO Promoter Holding
| Pre Issue Share Holding |
95.06% |
| Post Issue Share Holding |
73% |
Rossari Biotech IPO for NRI
Rossari Biotech Limited, the largest manufacturer of textile specialty chemicals in India is launching its IPO on 13th July 2020. The issue close date is 15th July 2020. The NRIs are allowed to subscribe to this IPO subject to certain rules and restrictions.
Rules and restrictions for NRI in Rossari Biotech IPO:
- NRIs can apply in IPO using ASBA form.
- The payment will be accepted only in Indian rupee or freely convertible foreign exchange.
- Eligible NRIs bidding on a repatriation basis should apply using blue colour Bid cum Application form meant for Non-Residents via the funds from the NRE or FCNR account.
- Eligible NRIs bidding on a non-repatriation basis should apply using white colour Bid cum Application Form meant for residents via the funds from the NRO account.
- Bids by Eligible NRIs for a bid amount of less than ₹200,000 would be considered under the Retail Category and the bid amount exceeding ₹200,000 would be considered under the Non-Institutional Category for the allocation purpose in the Offer.
Rossari Biotech IPO Investors Portion
- QIB: Not More than 50% of the offer
- NII: Not less than 15% of the offer
- Retail: Not less than 35% of the offer
by Ashok Kuumar | Jul 11, 2020 | Shares
OPEN DEMAT ACCOUNT IN 10 Minutes – CLICK HERE
Incorporated in 2003, Headquartered in Mumbai Yes Bank is a private sector bank in India. It has developed as a full-service commercial bank offering banking and technology-driven product and services to fulfill the financial needs of MSME, corporate, and retail customers.
Yes Bank provides merchant banking, investment banking, and brokerage businesses through Yes Securities. The mutual fund business of the company is handled by YES Asset Management (India) Limited, a subsidiary of Yes Bank. It has a pan-India presence across 28 states and 8 Union Territories. One representative office of the bank is also established in Abu Dhabi in March 2020. As of March 31, 2020, the bank has 1,135 branches and 1,423 ATMs. Yes Bank has presence in metro, urban, semi-urban and rural locations across India.
Product and Services:
1. Investment Banking Solutions
2. Yes First Corporate Credit Card
3. Yes Prosperity Purchase Credit Card
4. Treasury and Risk Management Solutions
5. Loans
6. Transactions Banking Solutions
7. Debt Capital Markets
8. Surplus and Investments
9. Digital Banking
After Yes Bank collapse in 2019, SBI has bought around 49% stake and became the shareholder in the company.
The bank is set to launch FPO (follow-on public offer) in the middle of this July to recover from the huge bad debt and generate funds from the share sale to enhance the capital base.
Competitive Strengths
1. Public-private ownership model
2. Strong technology backbone
3. Strong focus on retail and SME advances
4. Pan India presence
Company Promoters:
Yes Bank is professionally managed and it doesn’t have any identifiable promoter.
Company Financials:
Summary of financial Information (Restated)
| Particulars |
For the year/period ended (₹ in Million) |
|
31-Mar-20 |
31-Mar-19 |
31-Mar-18 |
| Total Assets |
2,578,321.64 |
3,808,596.10 |
3,124,496.54 |
| Total Revenue |
103,350.56 |
144,879.93 |
130,323.20 |
| Profit After Tax |
(164,325.80) |
17,092.66 |
42,332.20 |
Objects of the Issue:
The proposed utilisation of the net proceeds is for ensuring adequate capital to support growth and expansion, including enhancing the bank’s solvency and capital adequacy ratio.
Yes Bank FPO Details
| IPO Date |
Jul 15, 2020 – Jul 17, 2020 |
| Issue Type |
Book Built Issue FPO |
| Issue Size |
[.] Eq Shares of ₹2
(aggregating up to ₹15,000.00 Cr) |
| Fresh Issue |
[.] Eq Shares of ₹2
(aggregating up to ₹15,000.00 Cr) |
| Face Value |
₹2 Per Equity Share |
| IPO Price |
₹12 to ₹13 Per Equity Share |
| Employee Discount |
₹1 per share |
| Market Lot |
1000 Shares |
| Min Order Quantity |
1000 Shares |
| Listing At |
BSE, NSE |
Yes Bank FPO Tentative Date / Timetable
| Bid/Offer Opens On |
Jul 15, 2020 |
| Bid/Offer Closes On |
Jul 17, 2020 |
| Finalisation of Basis of Allotment |
Jul 22, 2020 |
| Initiation of Refunds |
Jul 23, 2020 |
| Credit of Shares to Demat Acct |
Jul 24, 2020 |
| IPO Shares Listing Date |
Jul 27, 2020 |
Yes Bank FPO Lot Size and Price (Retail)
| Application |
Lots |
Shares |
Amount (Cut-off) |
| Minimum |
1 |
1000 |
₹13,000 |
| Maximum |
15 |
15000 |
₹195,000 |
Note
- QIB: 50% of the net offer; NIB: 15% of the net offer; Retail: 35% of the net offer
- Employee reservation portion: ₹200 cr
- Employee discount: ₹1 per share
by Ashok Kuumar | Jul 7, 2020 | Investments
Bond Investment is Safe :
Bond investment is one of best option to earn various rate of interest for long term. As we all aware that rate of interest of Bank and other schemes are going down day by day. Hence Bond investment is good option to create wealth and can generate Yield upto 11% also.
For investment in Bond DEMAT is Required. So Please open DEMAT Account on Single Click
This is instructions to OPEN DEMAT Account. For any Help please write us [email protected], [email protected] or whatsapp@9891423442
Please view my share video. This may help you to understand better.
You can view current offering Bond and there rates also. Click here to see today offers.
Some of Bonds are for your reference.
955000.00 -25000.00 (-2.55%)
07 Jul 20 | 16:00 | All Prices in
| Previous Close |
980000.00 |
|
| Open |
955000.00 |
|
| High |
955000.00 |
|
| Low |
955000.00 |
|
| VWAP |
955,000.00 |
| 52 Wk High |
984,000.00 |
|
| 52 Wk Low |
953,000.00 |
|
| Upper Price Band |
11,76,000.00(20%) |
|
| Lower Price Band |
7,84,000.00(20%) |
|
| 2W Avg Qty` |
3 |
| TTQ |
2 |
|
| Turnover(Lakh) |
19.1 |
|
| Mcap Full (Cr.) |
— |
|
| Mcap FF (Cr.) |
— |
|
| Face Value |
1,000,000.00 |
| Issuer Name |
U P Power Corporation Ltd |
|
| YTM % at LTP |
— |
|
| Next Interest Payment date / Ex Date |
20 Jul 2020/ — |
|
| Coupon % |
10.15 |
|
| Maturity Date |
20 Jan 2028 |
| Rating |
IND A+(SO) |
|
| Category |
Listed |
|
| Group |
F |
|
| Var/ELM (%) |
10/– |
|
| Industry |
– |
1107350.13 +17188.13 (+1.58%)
01 Jul 20 | 16:00 | All Prices in
| Previous Close |
1090162.00 |
|
| Open |
1107350.13 |
|
| High |
1107350.13 |
|
| Low |
1107350.13 |
|
| VWAP |
1,107,350.00 |
| 52 Wk High |
1,107,350.13 |
|
| 52 Wk Low |
1,032,152.10 |
|
| Upper Price Band |
13,28,820.15(20%) |
|
| Lower Price Band |
8,85,880.11(20%) |
|
| 2W Avg Qty` |
2 |
| TTQ |
2 |
|
| Turnover(Lakh) |
22.15 |
|
| Mcap Full (Cr.) |
— |
|
| Mcap FF (Cr.) |
— |
|
| Face Value |
1,000,000.00 |
| Issuer Name |
State Bank Of India, |
|
| YTM % at LTP |
— |
|
| Next Interest Payment date / Ex Date |
–/ — |
|
| Coupon % |
9.37 |
|
| Maturity Date |
30 Dec 2099 |
| Rating |
CRISIL AA+/STABLE |
|
| Category |
Listed |
|
| Group |
F |
|
| Var/ELM (%) |
10/– |
|
| Industry |
Banks |
